Date:11/12/2009

quality of care, and reduce the cost of care, risks related to our belief that Masimo SET will deliver sufficient sensitivity and specificity to deliver the most accurate and reliable measurements under all conditions of patient motion and low peripheral perfusion, and risks related to our assumption that Masimo SET will help improve the regulation and delivery of oxygen therapy to neonates, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these forward-looking statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

    Media Contacts:
    Dana Banks
    Masimo Corporation
    +1 (949) 297-7348

Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8, Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered trademarks of Masimo Corporation.

SOURCE Masimo

'/>"/>

SOURCE Masimo Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
2. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
3. CareFusion Shipping Ventilators to CDC for National Emergency Preparedness
4. CareFusion Moves First Quarter Earnings Announcement to November 5
5. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. StatSure Signs Strategic Financing and License Deals with Inverness Medical Innovations
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
10. New AVEENO(R) Eczema Care Product Line Offers Breakthrough Formulas to Help Manage the Signs and Symptoms of Eczema
11. ALS Therapy Development Institute Signs Collaboration Agreement with the Allen Institute for Brain Science